Form 4: Stoke Therapeutics Director Receives Stock Option Grant

Director Jennifer Burstein was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Jennifer Burstein received a grant of 17,786 stock options on June 3, 2026.
• The options have an exercise price of $29.46 per share.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or strategic direction.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The options vest in one year or upon the next annual meeting, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, aligning director incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.
• The use of annual vesting cycles is a standard governance practice to ensure ongoing commitment from board members.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the next annual meeting date.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Options, Director Compensation